mercredi 22 avril 2020

Onco Actu du 22 avril 2020


4.16 DÉP., DIAG. & PRONO. - PANCRÉAS



Pancreatic Cancer Clinical Risk Prediction Appears to Improve With Genetic, Biomarker Data [Genome Web]











New risk prediction model could identify those at higher risk of pancreatic cancer [EurekAlert!]










5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS



Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells [Gilead]











Amid remdesivir craze Gilead finds time for another oncology pact — looping in all things NK cells [EndPoints]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



How cancer cells don their invisibility cloaks [UT Southwestern]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma [Novartis]











5.2.6 PHARMA - BIOTECH



Short attack targets one of the favorites now sharing the lead in the popular KRAS drug development race [EndPoints]











5.3 TRAITEMENTS - FDA, EMA,...



IMBRUVICA® (ibrutinib) Receives 11th FDA Approval [AbbVie]











FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia [FDA]










5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



AbbVie, J&J blockbuster Imbruvica rakes in 11th FDA approval, as competitors work on eroding franchise [EndPoints]











5.4.1 TRAITEMENTS - ECONOMIE - NICE



Larotrectinib for treating NTRK fusion-positive solid tumours [NICE]











New breed of personalised cancer medicine approved in England. What does it mean for patients? [Cancer Research UK]










6.1 OBSERVATION



Deaths from Metastatic Melanoma Drop Substantially in the United States [NCI]